Related Experiment Videos

Dextrorphan reduces infarct volume, vascular injury, and brain edema after ischemic brain injury

C Du1, R Hu, C Y Hsu

  • 1Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Insights

Dextrorphan (DX) reduces brain damage after stroke by protecting the blood-brain barrier and decreasing brain edema. Early post-stroke treatment with DX is effective in mitigating ischemic injury.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cerebrovascular Research

Background:

  • Focal cerebral ischemia can lead to significant brain damage, including infarcts, blood-brain barrier (BBB) breakdown, and edema.
  • NMDA receptor activation is implicated in the pathophysiology of ischemic brain injury.

Purpose of the Study:

  • To investigate the neuroprotective effects of Dextrorphan (DX) in a rat model of focal cerebral ischemia.
  • To determine if DX can mitigate infarct volume, BBB breakdown, and brain edema following ischemic stroke.

Main Methods:

  • Focal cerebral ischemia was induced in rats by temporary middle cerebral artery (MCA) and common carotid artery (CCA) ligation.
  • Infarct volume, BBB permeability (using FITC-dextran), and brain edema were assessed after 90 minutes of ischemia and reperfusion.
  • Dextrorphan (DX) was administered at various doses before or after ischemia.

Main Results:

  • DX administration before ischemia dose-dependently reduced infarct volume, with optimal protection at 30 mg/kg (U-shaped dose-response).
  • Post-treatment with DX 30 minutes after ischemia was effective, but not at 60 minutes.
  • DX (30 mg/kg) significantly reduced post-ischemic BBB breakdown and brain edema in the affected cortical area.

Conclusions:

  • NMDA receptor activation plays a role in BBB disruption and brain edema formation after ischemic stroke.
  • Dextrorphan (DX) exhibits neuroprotective effects against ischemic brain injury, likely through modulation of NMDA receptor activity.
  • DX demonstrates potential as a therapeutic agent for acute ischemic stroke, particularly when administered early.

Related Concept Videos